Lialda Shire plc - Treatment for Ulcerative Colitis
Lialda is a once-daily oral formulation of mesalamine indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.Posted: January 2007
Related articles
- Lialda (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis - July 18, 2011
- FDA Approves Lialda (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis - January 16, 2007
- Shire Provides Update on U.S. Marketing Application of Mesavance (mesalamine) With MMX Technology - September 8, 2006
- Shire Announces Filing of Mesavance (mesalamine) for Treatment of Ulcerative Colitis - December 22, 2005
Lialda (mesalamine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
